INOVIQ Ltd (ASX:IIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions to improve the diagnosis and treatment of cancer and other diseases. Our exosome-based products include an ovarian cancer screening test (clinical development) and CAR-exosome therapy for triple negative breast cancer (preclinical development) and exosome enrichment tools and services (on market for research use). Other products in our pipeline include a breast cancer monitoring test based on glycan-binding technology that has the potential to improve sensitivity and specificity for a range of cancers (clinical development) and a bladder cancer immunocytochemistry assay (on market).

Why work with us

We provide exosome enrichment tools and services including EXO-NET pan exosome capture tool and services including exosome isolation, developing tools to capture specific exosome populations, biomarker discovery and diagnostics development. We are also seeking partnerships for our clinical development stage diagnostics including EXO-OC for ovarian cancer screening and neuCA15-3 for breast cancer monitoring.